Business Analysis of Abbvie

 Analyze Historical Performance, Strategic Priorities, And Business Improvement Opportunities of Abbvie

Business Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Abbvie

Abbvie


R&P Rank: 106
Sector: Life Sciences
Industry:Biotechnology
H.Q Location:Illinois
Website: www.abbvie.com
Company Address:
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Ph:847-932-7900

Business Analysis of Abbvie

The Life Sciences Sector is witnessing a major shakeup, new age business models in the industry are transforming both customers and businesses. Faced with this uncertainity, companies are investing resources to transform their business. An in-depth business analysis is a valuable resource to identify and articulate the need for a business model change. At R&P Research we believe, the starting point for a business analysis is Benchmarking. Business benchmarking can be done at various levels: 1) Industry Benchmarking 2) Peer Benchmarking 3) Disruptors Benchmarking. In this report, we share the snapshot of how Abbvie compares against the industry on the major performance indicators. This analysis, along with peer group/disruptors benchmarking and revenue model understanding can help identify growth and cost optimization opportunities to maximize the value delivered by Abbvie to its stakeholders. R&P Research Industry Intelligence Platform provides historical data for last 15 years with an easy to use benchmarking interface for an in-depth comparative business analysis.

Here is the performance snapshot of Abbvie with an interactive chart.

  1. Revenue Growth: Abbvie reported a revenue growth of 12.2% year-on-year during 2016. Biotechnology Industry grew at 7.0% in the same period
  2. COGS share of Revenues: As a percentage of revenue, Abbvie spent 22.8% of its total revenues on COGS. Biotechnology industry average (COGS share of revenue) in the same period was 15.0%
  3. R&D share of Revenues: As a percentage of revenue, Abbvie spent 17.0% of its total revenues on R&D. Biotechnology industry average R&D spending in the same period was 23.7%
  4. SG&A share of Revenues: As a percentage of revenue, Abbvie spent 22.8% of its total revenues on Sales, Marketing, and General Administration (SG&A). Biotechnology industry average SG&A spending in the same period was 20.7%
  5. Inventory share of Revenues: As a percentage of revenue, Abbvie spent 5.6% of its total revenues on Inventories. Biotechnology industry average Inventory spending in the same period was 7.5%
  6. Accounts Payable share of Revenues: As a percentage of revenue, Abbvie invested 36.6% of its total revenues on Accounts Payable (A/P) Biotechnology industry average Accounts Payable investment in the same period was 11.8%
  7. Accounts Receivable share of Revenues: As a percentage of revenue, Abbvie invested 18.6% of its total revenues on Accounts Receivable (A/R). Biotechnology industry average Accounts Receivable investment in the same period was 16.6%
  8. PP&E share of Revenues: As a percentage of revenue, Abbvie invested 10.2% of its total revenues on Property, Plants, and Equipments (PP&E). Biotechnology industry average PPE investment in the same period was 17.0%
  9. Intangibles share of Revenues: As a percentage of revenue, Abbvie invested 172.8% of its total revenues on Intangibles. Biotechnology industry average Intangibles investment in the same period was 96.4%
  10. Net Margins: Abbvie Net Margins in the year 2016 were 23.2%. Biotechnology industry average Net Margins in the same period were 26.6%

Sector and Industry Association of Abbvie

For the purpose of performance benchmarking of a company with a sector or industry average, R&P Research associates every company with one sector and one industry. An industry consists of companies with related/similar business models. A sector comprises of a group of related/similar industries. For high-level analysis purposes, related/similar sectors are grouped into sector groups.

Abbvie is associated with Healthcare Sector Group, Life Sciences Sector, and Biotechnology Industry.

Life Sciences sector is comprised of the following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. The definitions for each of the industries is as follows:

  • Pharmaceuticals industry includes companies that discover, develop, manufacture, and market medicines licensed for use as medications. In general these companies offer pharmaceutical products that can be described as prescription or over-the-counter medicines. Many Pharmaceutical companies also offer a diverse portfolio of animal health products, services and solutions. Many diversified pharmaceutical companies operate in more than two operating segments like consumer health products, medical devices and pharmaceutical.
  • Medical Devices industry includes manufacturers and distributors of medical equipments and medical supplies. Medical equipments include large scale capital equipmets such as X-Ray machines and MRI scanners and other nondisposable medical devices like stents and pacemakers. Medical supplies include makers of contact lenses, eyeglass lenses, bandages and other disposable products.
  • Biotechnology industry includes Biotechnology product companies, subscription companies, and service companies. Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from, or semi synthesized from biological sources. Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies.
  • Diagnostics & Scientific Instruments industry includes companies that provide testing products, diagnostic reagents, instruments and diagnostic services to aid in the detection and treatment of a wide range of diseases. It also includes molecular diagnostic and genetic testing companies that develop, manufacture, market and provide diagnostic tests, diagnostic systems and related products and services. Also included are companies that manufacture and market analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics.

Industry Ranking of Abbvie

With $25.6 billion revenues, Abbvie ranked number 2 of all the companies in the US Biotechnology industry. There were a total of 45 public companies in the US Biotechnology industry that had revenues greater than $50 million during 2016.

The top-10 companies in the US Biotechnology industry by revenues during 2016 were:

  1. Gilead Sciences ($30.4 billion)
  2. Abbvie ($25.6 billion)
  3. Amgen ($23 billion)
  4. Biogen ($11.4 billion)
  5. Celgene ($11.2 billion)
  6. Regeneron ($4.9 billion)
  7. Alexion Pharmaceuticals ($3.1 billion)
  8. Vertex Pharmaceuticals ($1.7 billion)
  9. United Therapeutics ($1.6 billion)
  10. BioMarin Pharmaceutical ($1.1 billion)

Business Model Analysis (BMA) Framework

We use the following framework to assess the business model of a company. Business Model Analysis framework can be used by organizations to articulate growth strategies and identify cost optimization opportunities. Technology and consulting companies can use this framework to identify the value drivers and pain points of their targeted customers. Entrepreneurs can use this framework to understand the language of business and identify promising business opportunities. This framework can be used by any professional aspiring to take up a leadership role to better understand the businesses challenges, articulate growth strategy, and monitor the business improvement requirements for the organization.

Next Steps

  • Conduct a holistic benchmarking; to identify and target additional sources of value
  • Get in touch with us to learn more about Business Model Analysis Framework
  • Get free data, charts, and analysis of Abbvieand its peers on select key performance indicators by clicking the reports provided below

Industry Peers and Competitors of abbvie

Gilead Sciences (GILD) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Gilead Sciences Inc with $30 billion revenues in the year 2016 was the number 1 Biotechnology company. Read this report to know the top competitors of Gilead Sciences and identify growth and cost optimization opportunities of Gilead Sciences

Amgen (AMGN) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Amgen Inc with $23 billion revenues in the year 2016 was the number 3 Biotechnology company. Read this report to know the top competitors of Amgen and identify growth and cost optimization opportunities of Amgen

Biogen (BIIB) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Biogen Inc. with $11 billion revenues in the year 2016 was the number 4 Biotechnology company. Read this report to know the top competitors of Biogen and identify growth and cost optimization opportunities of Biogen

Celgene (CELG) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Celgene Corp with $11 billion revenues in the year 2016 was the number 5 Biotechnology company. Read this report to know the top competitors of Celgene and identify growth and cost optimization opportunities of Celgene

Regeneron (REGN) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Regeneron Pharmaceuticals Inc with $5 billion revenues in the year 2016 was the number 6 Biotechnology company. Read this report to know the top competitors of Regeneron and identify growth and cost optimization opportunities of Regeneron

Alexion Pharmaceuticals (ALXN) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Alexion Pharmaceuticals Inc with $3 billion revenues in the year 2016 was the number 7 Biotechnology company. Read this report to know the top competitors of Alexion Pharmaceuticals and identify growth and cost optimization opportunities of Alexion Pharmaceuticals

Revenues Analysis

Abbvie (ABBV) Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Abbvie Inc. (ABBV) from 2012 to 2016. Abbvie generated a total of $25.6 billion revenues during 2016. Abbvie reported a revenue growth of 12.2% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Abbvie (ABBV) Revenues And Revenue Growth From 2009 To 2016

This report provides the last eight years revenues and revenue growth of Abbvie Inc. (ABBV) from 2009 to 2016. Abbvie generated a total of $25.6 billion revenues during 2016. Abbvie reported a revenue growth of 12.2% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Abbvie (ABBV) Revenue Growth Comparison With Industry Growth From 2012 To...

This report provides a comparison of Abbvie Inc. (ABBV) revenue growth with Biotechnology industry growth during the last five years from 2012 to 2016. Abbvie reported a revenue growth of 12.2% year-over-year during 2016. The Biotechnology industry growth was 7% year-over-year during 2016. Abbvie growth was faster than the industry during 2016.

Profit Analysis